Review of the effect of suspension and re-treatment of ixekizumab on moderate-to-severe psoriasis vulgaris

A tétel rövid nézete
dc.contributor.advisorGáspár, Krisztián
dc.contributor.advisordeptDebreceni Egyetem::Általános Orvostudományi Kar::Bőrgyógyászati Klinikahu_HU
dc.contributor.authorBlanco Crespo, Ana
dc.contributor.departmentDE--Általános Orvostudományi Karhu_HU
dc.contributor.opponentPapp, Gábor
dc.contributor.opponentSawhney, Irina
dc.contributor.opponentdeptSporttudományi Koordinációs Intézethu_HU
dc.contributor.opponentdeptDebreceni Egyetem::Általános Orvostudományi Kar::Bőrgyógyászati Klinikahu_HU
dc.date.accessioned2021-06-18T11:04:55Z
dc.date.available2021-06-18T11:04:55Z
dc.date.created2020-05-07
dc.description.abstractPsoriasis is a papulosquamous chronic skin disease that requires life-long management. Ixekizumab (IXE) is a high-affinity selective monoclonal antibody against interleukin (IL)-17A which is registered treating moderate-to-severe plaque psoriasis. The purpose of this thesis work is to assess the outcomes of patients who interrupted the treatment and were subsequently retreated with IXE, as well as to investigate if after the temporary suspension the patients will ever be able to reach again their best clinical score obtained before. Information was collected from patients available in the Department of Dermatology, in the University of Debrecen. The investigation was authorized by the Local Ethics Committee (H.0046-2019). The patients started the normal regimen of IXE, after induction, receiving 80 mg every 4 weeks until the treatment was stopped. After that, further financial support was requested from responsible bureaus for the treatment continuation. Waiting upon approval patients were suspended an average of 94 days until re-start was realized. After an average of 24 weeks of the re-start of the treatment, 75% of the patients reached symptom-free state, and the rest improved an average of 85% compared to their clinical status at the beginning of re-start. IXE demonstrated to be highly effective in the clearance of psoriatic skin even after the treatment was interrupted taking a relatively short time to regain efficacy and with no encountered clinically significant side effects.hu_HU
dc.description.courseáltalános orvoshu_HU
dc.description.courselangangolhu_HU
dc.description.degreeegységes, osztatlanhu_HU
dc.format.extent32hu_HU
dc.identifier.urihttp://hdl.handle.net/2437/311369
dc.language.isoenhu_HU
dc.subjectPsoriasis vulgarishu_HU
dc.subjectIxekizumabhu_HU
dc.subject.dspaceDEENK Témalista::Orvostudomány::Bőrgyógyászathu_HU
dc.titleReview of the effect of suspension and re-treatment of ixekizumab on moderate-to-severe psoriasis vulgarishu_HU
Fájlok
Gyűjtemények
Theses (Faculty of Medicine)